LINDIS Biotech

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab

Catumaxomab received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for the treatment of malignant ascites Pharmanovia will lead all activities to launch catumaxomab Partnership underscores potential of this unique immunotherapy; development in further...
Zeppelinstraße 4, 82178 Puchheim, Germany

+49 89 45239600